Arquivos Brasileiros de Endocrinologia & Metabologia
Print version ISSN 0004-2730
AMORIM, Pollyana Garcia et al. Growth hormone in children and adolescents with cystic fibrosis. Arq Bras Endocrinol Metab [online]. 2011, vol.55, n.9, pp. 671-676. ISSN 0004-2730. http://dx.doi.org/10.1590/S0004-27302011000900001.
The recombinant human growth hormone (rhGH) can improve weight gain, physical growth, clinical and lung in cystic fibrosis (CF). However, the routine use, although promising, is not established in the literature. The objective of this study was to assess the benefits of rhGH in children and adolescents with CF. We conducted a systematic review in the database PubMed, Lilacs, SciELO and Cochrane, in the period 2000-2010, using the keywords: "cystic fibrosis", "growth hormone", "children" and "adolescents". We found 77 articles and included 11 randomized controlled trials, with 290 children and adolescents with CF. The short-term use (1-24 months) of rhGH improved the height, weight, growth rate, bone mineral content and components of pulmonary function. Adverse effects, like diabetes, were not observed in the studies. The short-term use of rhGH improved growth and body composition in patients with CF.
Keywords : Growth hormone; cystic fibrosis; adolescent health and children.